• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New report shows more than 220 drugs in pipeline for diabetes

New report shows more than 220 drugs in pipeline for diabetes

November 15, 2012
CenterWatch Staff

America's biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the U.S. affected by diabetes.

These medicines in development—all in either clinical trials or under review by the FDA— include 32 for type 1 diabetes, 130 for type 2 and 64 for diabetes-related conditions, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

"Diabetes is a serious chronic disease with far-reaching implications for American patients, families, our health care system and our economy," said John J. Castellani, president and CEO, PhRMA. "However, diabetes can be controlled through lifestyle interventions. And treatment with medications can also manage and slow the disease. The medicines in the pipeline represent an exciting new chapter in the ongoing quest to better treat this debilitating disease."

Since 1990, six new classes of type 2 diabetes medicines have been approved by FDA, giving patients and providers powerful new tools to treat the condition. Examples of the potential innovations outlined in the report include:

  • A once-daily medicine that selectively inhibits the protein associated with glucose metabolism.
  • A medicine designed to inhibit an enzyme linked to diabetic neuropathy.
  • A medicine to treat type 2 diabetes that may allow for once-weekly dosing.

One in 10 American adults has diabetes now and as many as one in three could face the disease by 2050 if current trends continue, according to the Centers for Disease Control and Prevention. In addition to the terrible human toll associated with these outcomes, the economic consequences of diabetes are enormous. In 2007, the cost of diabetes in the U.S. was $174 billion. If the additional costs of undiagnosed diabetes ($18 billion), pre-diabetes ($25 billion) and gestational diabetes ($623 million) are factored, the total annual cost of diabetes in the U.S. amounts to $218 billion.

Improved adherence to diabetes medications can lead to better health outcomes and reduced costs. According to recent research, patients with diabetes who do not consistently take their medicines as prescribed are 2.5 times more likely to be hospitalized than those who follow their prescribed treatment regimens more than 80% of the time.

In addition, a recent study in Health Affairs projected that improved adherence to diabetes medications could result in more than one million emergency room visits and close to 620,000 hospitalizations annually, for a total potential savings of $8.3 billion annually.

"Many of the human and economic costs associated with diabetes can be avoided, making improvement of patient adherence one of the best opportunities to get better results and greater value from our health care system," Castellani added. "This is by no means an easy task, but stakeholders throughout the health care system— including biopharmaceutical research companies—must work together to tackle this shared objective."

In conjunction with the report, PhRMA is releasing an array of multi-media materials on diabetes research and care, including perspectives from biopharmaceutical researchers, patient groups and professional organizations. A new infographic will appear in a special issue of the Financial Times, slated for release November 14.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing